MAIA Biotechnology, Inc. (MAIA) is a Healthcare stock trading at $1.39 (as of 2026-06-18), with a market capitalization of $84.51M and a trailing P/E of -2.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
MAIA Biotechnology, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of cancer therapies, primarily for non-small cell lung cancer. Its lead investigational candidate, THIO, is designed around telomere targeting and immunogenicity. The company is based in Chicago and was founded in 2018.